| Maternal caffeine consumption during pregnancy and risk of low birth weight: A dose-response meta-analysis of observational studies J Rhee, R Kim, Y Kim, M Tam, Y Lai, NN Keum, CE Oldenburg PloS one 10 (7), e0132334, 2015 | 159 | 2015 |
| One‐step, zero‐background ligation‐independent cloning intron‐containing hairpin RNA constructs for RNAi in plants G Xu, N Sui, Y Tang, K Xie, Y Lai, Y Liu New Phytologist 187 (1), 240-250, 2010 | 81 | 2010 |
| Cost-effectiveness of pembrolizumab versus carboplatin-based chemotherapy as first-line treatment of PD-L1–positive locally advanced or metastatic urothelial carcinoma … O Hale, K Patterson, Y Lai, Y Meng, H Li, JL Godwin, BH Moreno, ... Clinical Genitourinary Cancer 19 (1), e17-e30, 2021 | 25 | 2021 |
| The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States RL Slater, Y Lai, Y Zhong, H Li, Y Meng, BH Moreno, JL Godwin, T Frenkl, ... Journal of medical economics 23 (9), 967-977, 2020 | 18 | 2020 |
| Virus-Induced Gene Silencing Using Artificial miRNAs in Nicotiana benthamiana Y Tang, Y Lai, Y Liu Virus-Induced Gene Silencing: Methods and Protocols, 99-107, 2013 | 18 | 2013 |
| Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States R Aguiar-Ibáñez, C Hardern, F van Hees, D Lee, A Patel, N Chhabra, ... Journal of Medical Economics 25 (1), 469-480, 2022 | 17 | 2022 |
| Cost-effectiveness of navigated radiofrequency ablation for hepatocellular carcinoma in China Y Lai, K Li, J Li, SX Liu International Journal of Technology Assessment in Health Care 30 (4), 400-408, 2014 | 9 | 2014 |
| Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in the United States Y Lai, AG Bensimon, E Gao, R Bhattacharya, R Xu, J Chevure, K Imai, ... Clinical Genitourinary Cancer 21 (5), 612. e1-612. e11, 2023 | 4 | 2023 |
| Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan. L Wang, AG Bensimon, M Sundaram, R Xu, Y Lai, Y Liu, S Mt-Isa, D Yang, ... Journal of Clinical Oncology 41 (6_suppl), 733-733, 2023 | 4 | 2023 |
| Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial … D Gelb, Y Zhong, RF Perini, JL Godwin, Y Lai, S Arndorfer, M Lorenzi, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 1 | 2019 |
| Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States. Y Lai, Y Zhong, H Li, K Patterson, O Hale, Y Meng, TL Frenkl, JL Godwin, ... Journal of Clinical Oncology 37 (27_suppl), 93-93, 2019 | 1 | 2019 |
| EE671 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Renal Cell Carcinoma Post-Nephrectomy in France M Apert, L Bensimon, L Marié, M Chau, G Baluni, N Chhabra, A Kundu, ... Value in Health 26 (12), S183, 2023 | | 2023 |
| EE371 Disease Management Costs for Patients With Intermediate-High or High-Risk Renal Cell Carcinoma (RCC) Following Nephrectomy Y Lai, Y Song, S Zhang, R Bhattacharya, C Carley, A Bensimon Value in Health 25 (12), S128, 2022 | | 2022 |
| PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib A Bensimon, Y Lai, R Xu, R Bhattacharya, R Shinde Value in Health 25 (7), S554, 2022 | | 2022 |
| Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States. Y Zhong, Y Lai, H Li, R Batteson, Y Meng, TL Frenkl, JL Godwin, ... Journal of Clinical Oncology 37 (15_suppl), e16010-e16010, 2019 | | 2019 |
| Novel DNA-beta associated molecules produced by sequence recombination and deletion of cotton leaf curl Multan virus complex Y Lai, K Xie, J Cai, B Qin, Y Liu Wei sheng wu xue bao= Acta microbiologica Sinica 52 (7), 832-839, 2012 | | 2012 |
